Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Cash from Operations: 2020-2025

Historic Cash from Operations for GeneDx Holdings (WGS) over the last 5 years, with Sep 2025 value amounting to $15.8 million.

  • GeneDx Holdings' Cash from Operations rose 458.75% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $33.2 million, marking a year-over-year increase of 160.15%. This contributed to the annual value of -$28.5 million for FY2024, which is 84.18% up from last year.
  • GeneDx Holdings' Cash from Operations amounted to $15.8 million in Q3 2025, which was up 51.31% from $10.4 million recorded in Q2 2025.
  • GeneDx Holdings' 5-year Cash from Operations high stood at $15.8 million for Q3 2025, and its period low was -$88.4 million during Q3 2022.
  • Moreover, its 3-year median value for Cash from Operations was -$4.5 million (2024), whereas its average is -$15.7 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 19,292.69% in 2021, then skyrocketed by 458.75% in 2025.
  • Quarterly analysis of 5 years shows GeneDx Holdings' Cash from Operations stood at -$52.0 million in 2021, then fell by 24.37% to -$64.7 million in 2022, then surged by 53.82% to -$29.9 million in 2023, then spiked by 89.34% to -$3.2 million in 2024, then skyrocketed by 458.75% to $15.8 million in 2025.
  • Its Cash from Operations stands at $15.8 million for Q3 2025, versus $10.4 million for Q2 2025 and $10.2 million for Q1 2025.